# Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

> **NCT02614898** · — · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome

## Interventions

- **OTHER:** Eculizumab

## Key facts

- **NCT ID:** NCT02614898
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-04
- **Primary completion:** 2017-10-05
- **Final completion:** 2017-10-05
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Terminated for administrative reasons before enrollment was complete.
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614898, "Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02614898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*